Evidence map›Paper›PMID 42883985›Full record

ReviewInternational journal of molecular sciences2026

Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance.

Robert N Nishimura, Joseph F Gera

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert N NishimuraDepartments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Joseph F GeraDepartment of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, 16111 Plummer Street (151), Building 1, Room C111A, Los Angeles, CA 91343, USA.ORCID 0000-0002-2908-6894

Funding

Targeting circRNA translation in glioblastomaR01CA278783 · NCI · GREATER LOS ANGELES VETERANS RESEARCH AND EDUCATION FOUNDATION · PI JOSEPH F GERA · 2024 to 2026
$941k
BLRD VA I01 BX002665NCI NIH HHS R01 CA278783
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common and highly malignant primary brain tumor in adults. Even with advances in surgery, radiotherapy, and systemic therapies, patient outcomes remain poor due to extensive intratumoral heterogeneity and the development of therapeutic resistance. Circular RNAs (circRNAs) are a class of covalently closed RNA molecules that are highly abundant in the central nervous system and frequently dysregulated in cancer. While originally considered non-coding transcripts, current evidence demonstrates that a subset of circRNAs contain functional open reading frames and can undergo cap-independent translation to generate biologically active proteins and peptides. Recent studies have identified a growing number of translated circRNAs in GBM encoding proteins implicated in diverse processes such as receptor tyrosine kinase signaling, DNA repair, metabolism, stemness, invasion, and therapeutic resistance. These findings expand the coding potential of the GBM transcriptome and highlight an additional layer of post-transcriptional regulation. In this review, we summarize our current understanding of circRNA translation, discuss the biological functions of translated circRNAs in GBM, and examine their potential roles in tumor progression, therapeutic resistance, and clinical management. Additionally, we consider the opportunities and challenges associated with targeting translated circRNAs and their encoded proteins for the treatment of GBM.

Indexed as

Brain NeoplasmsDrug Resistance, NeoplasmGlioblastomaProtein BiosynthesisRNA, CircularAnimalsDisease ProgressionGene Expression Regulation, NeoplasticHumansRNA, CircularbiomarkercircRNA-encoded proteinscircular RNA translationglioblastomanon-canonical translationprecision oncologytherapeutic resistance

Identifiers

PMID42883985
PMCPMC13664927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.